Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Fed Governor Bowman says December interest rate cut should be the last
Bowman said Thursday she supported the recent interest rate cuts but doesn’t see the need to go any further.
UnitedHealthcare CEO shooting: Photos show face of person sought by NYPD for questioning
UnitedHealthcare CEO Brian Thompson, whose company is the biggest private health insurance payer in the United States, was fatally shot in New York.
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to […]